Clonal origin of lineage switch leukemia following CAR-T cell and blinatumomab therapy
Children with ALL treated with anti-CD19 therapy occasionally develop a phenotypically distinct AML. However, the precise clonal origin of such class switch leukemias remains unresolved. Here, we reconstructed the evolution of leukemia in a child with primary ALL, two ALL relapses and AML after treatment with anti-CD19 CAR-T and blinatumomab through whole-genome sequencing. The phylogeny revealed that the AML was a monoclonal outgrowth descending from the initial ALL and harbored biallelic loss of CDKN2A, PAX5 and TP53. However, none of the ALL or AML relapses directly descended from one another, suggesting the presence of a reservoir of persistent clones. Our findings suggest anti-CD19 treatment selects pre-existing clones, with many key genetic alterations underpinning the lineage switch detectable prior to treatment.
- 8 samples
- DAC: EGAC00001000205
- Technology: Illumina NovaSeq 6000
Wellcome Trust Sanger Institute Data Sharing Policy
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Whole Genome Sequencing |
This table displays only public information pertaining to the files in the dataset. If you wish to access this dataset, please submit a request. If you already have access to these data files, please consult the download documentation.
| ID | File Type | Size | Located in | |
|---|---|---|---|---|
| EGAF00006702130 | 1659616221019 | 70.5 GB | ||
| EGAF00006702131 | 1659615321019 | 67.2 GB | ||
| EGAF00006702132 | 1659615321019 | 73.8 GB | ||
| EGAF00006702133 | 1659616221019 | 67.3 GB | ||
| EGAF00006702134 | 1659614421023 | 61.2 GB | ||
| EGAF00006702135 | 1659616221019 | 79.5 GB | ||
| EGAF00006702136 | 1659615321019 | 60.4 GB | ||
| EGAF00006702137 | 1659615321019 | 71.5 GB | ||
| 8 Files (551.5 GB) | ||||